Retinal Disorder Treatment Market (2024 - 2030)

Retinal Disorder Treatment Market Summary

The presence of promising pipeline products is expected to boost the market growth in the forecast period. The rising prevalence of retinal disorders is anticipated to propel market growth over the forecast period. For instance, as per the NCBI in 2020, in patients aged over 40, the prevalence of retinal disorders ranges between 5.35% and 21.02%. In developed nations, retinal disorders are the most common cause of irreversible blindness, as they are asymptomatic till the later stages of the disease.

Age-related macular degeneration treatment is expected to exhibit lucrative growth, as multiple market players are increasingly focusing on R&D to develop innovative treatments. Furthermore, the acquisition of promising molecules is on the rise. In December 2020, the rights for AMD gene therapy HMR59 were bought by Janssen Pharmaceutical.

The increasing number of innovative products for retinal disorders is creating new revenue generation channels for the players. For instance, in January 2022, Vabysmo by Roche was approved by the FDA for the treatment of wet age-related macular degeneration and macular edema in diabetic patients. The approval of this bispecific antibody is expected to enhance the management of patients. In July 2022, Iveric Bio paid DelSiTech for the development of sustained-release retinal disease prospects.

However, the high cost of novel drugs for retinal disorders is a major restraint. For instance, Luxturna, approved in 2017, is a one-time treatment for retina hereditary degeneration and is sold for USD 850,000 in the U.S., thus making it one of the world’s most expensive treatments. Luxturna is the first American therapeutic medication to emerge from gene therapy, which consists of repairing defective genes.

Type Insights

The macular degeneration segment held the largest market share of 43.6% in 2022, owing to the increasing prevalence of macular degeneration, regulatory support, and increasing interest of key players in the segment. For instance, in September 2021, the U.S. FDA approved a biosimilar referencing Lucentis named Byooviz, for the treatment of neovascular age-related macular degeneration (AMD), developed by Biogen Inc. and Samsung Bioepis Co., Ltd. In December 2022, two Korean firms Chong Kun Dang and Samsung Bioepis are expected to launch a biosimilar version of Lucentis for the treatment of age-related macular degeneration. Moreover, various studies are going on to develop novel therapeutics, for instance, in November 2022, REGENXBIO Inc. announced positive interim results for the ALTITUDE trial of RGX-314 used for the treatment of diabetic retinopathy.

The Diabetic retinopathy segment is expected to witness the fastest growth rate, which is attributable to the rising prevalence of the disorder. For instance, as per the NCBI in 2018, globally, 51% of the total population blindness is attributable to diabetic retinopathy and around 56% of people suffering from diabetic retinopathy come from the Asia-Pacific. The prevalence of diabetic retinopathy among those with diabetes ranged from 10% in India to 43% in Indonesia within the Asia-Pacific. In June 2022, Ocuphire Pharma, Inc. received a U.S. patent for APX3330, a late-stage oral drug candidate for the treatment of patients with diabetic retinopathy.

Dosage Form Insights

The eye drops dosage form segment held the largest market share in the global market in 2022 and is expected to show the fastest growth rate during the forecast period, owing to the cost-effectiveness and rising initiatives to develop novel eye drops for facilitating better absorption of the drugs. For instance, in July 2021, EyeCRO, a subsidiary of Charlesson LLC, announced its expansion into diabetic retinopathy treatment with eye drops of Fenofibrate. The step has been taken in order to enhance the availability of the medicine in the eye, which is limited when the treatment is taken orally. Moreover, the advent of generic formulations is further driving the market growth; for instance, in February 2022, the first generic of Restasis was approved by FDA.

The eye solution segment is expected to witness lucrative growth during the forecast period, owing to the increasing usage of injectable drugs for treatment. This includes major drugs such as Lucentis and Eylea. In addition, R&D is rising in the segment. For instance, AGN-241622, a pipeline drug of AbbVie Inc., is under phase III clinical trial for the treatment of presbyopia. The drug is an alpha-2 agonist and will be available as an ophthalmic solution.

Distribution Channel Insights

The hospital pharmacy segment held the highest market share in 2022. This can be attributed to the increasing use of drugs that require an injectable form of administration, which makes access to a hospital pharmacy easier. Moreover, hospitals offer extensive patient care, treatment, quick reimbursement, and insurance policies, owing to which patients opt for hospital pharmacies.

However, the online pharmacy distribution channel segment is expected to witness high growth over the forecast period. During the pandemic, there has been a direct spark that has accelerated the growth of e-commerce due to various travel restrictions and lockdowns across the globe. The online pharmacy also offers a number of benefits such as lower prices, discounts and offers, and convenience that further propel the growth of the segment.

Regional Insights

North America dominated the global market with a revenue share of 38.3% in 2022 and is anticipated to grow at a significant rate, driven by factors such as the growing geriatric population, the increasing launch of novel products, and enhanced awareness levels about eye conditions. As per BrightFocus Foundation, in 2019, 11 million people were suffering from AMD in the U.S., and the number is projected to double by 2050. With rising cases of the condition, there is a rising need for the development of effective therapeutics, which enable key players to launch newer drugs. For instance, in December 2022, Olix Pharmaceuticals completed the registration for phase 1 clinical trials of OLX301A for wet and dry muscular degeneration treatment in the U.S.

Asia Pacific is estimated to be the fastest-growing market during the forecast period owing to the increasing awareness among the population about early diagnosis & treatment, rising disposable income, and availability of effective and efficient treatment methods. For instance, as of 2021, India has 74 million diabetics, while 12.5 million of these suffer from diabetic retinopathy of some form. Thus, the presence of a high number of target patients is creating opportunities in the region.

Key Companies & Market Share Insights

Key players are rapidly opting for strategies such as strategic collaborations, geographical expansions, and partnerships through acquisitions and mergers in economically favorable and emerging regions. For instance, in March 2021, SemaThera Inc. announced a licensing agreement and a research collaboration with Roche in order to develop a new class of biologicals for the treatment of ischemic retinal diseases and diabetic retinopathy. Some of the key players in the global retinal disorder treatment market include:

• Santen Pharmaceutical Co., Ltd.

• Regeneron Pharmaceuticals Inc.

• Graybug Vision, Inc.

• Shire (Takeda Pharmaceutical Company Limited)

• Bayer AG

• Allergan plc. (AbbVie Inc.)

• Genentech, Inc. (F. Hoffmann-La Roche Ltd.)

• Acucela Inc.

• Pfizer, Inc.

• Kubota Pharmaceutical Holdings Co., Ltd.,

Retinal Disorder Treatment Market